INTRODUCTION
Glucagon-like peptide-1 (GLP-1) agonists are used to treat type 2 diabetes mellitus (T2DM) and have recently gained approval and popularity for treating obesity and weight loss. With the recent increase in prescriptions,1 a notable gap in the literature still exists regarding comprehensive evaluations and comparisons of cutaneous reactions in this medication class. This study aimed to characterize the types of cutaneous reactions seen across different GLP-1 agonists and to determine whether differences exist in reactions based on the reason for medication use.
Cutaneous adverse events (CAEs) to GLP-1 agonists were retrospectively reviewed using the FDA Adverse Event Reporting System (FAERS).2 Medications reviewed included: semaglutide, dulaglutide, tirzepatide, lixisenatide, liraglutide, and exenatide. Adverse events (AEs) reviewed were limited to those categorized as "Skin and Subcutaneous Tissue Disorders" reactions with a single suspected offending drug from the previously listed medications. Reactions were grouped into categories such as life-threatening, drug eruptions, eczematous reactions, etc, (Table 1). CAEs were then filtered and grouped into the reason for use in the following groups: T2DM, weight management (WM), and T2DM+WM. Chi-Square (or Fisher's
Cutaneous adverse events (CAEs) to GLP-1 agonists were retrospectively reviewed using the FDA Adverse Event Reporting System (FAERS).2 Medications reviewed included: semaglutide, dulaglutide, tirzepatide, lixisenatide, liraglutide, and exenatide. Adverse events (AEs) reviewed were limited to those categorized as "Skin and Subcutaneous Tissue Disorders" reactions with a single suspected offending drug from the previously listed medications. Reactions were grouped into categories such as life-threatening, drug eruptions, eczematous reactions, etc, (Table 1). CAEs were then filtered and grouped into the reason for use in the following groups: T2DM, weight management (WM), and T2DM+WM. Chi-Square (or Fisher's
